top of page

bloomly agency Group

Public·25 members
Kent Chaney
Kent Chaney

IFM_05-May 2021

Download File >>>

In March 2021, the FDA also approved isatuximab, in combination with carfilzomib and dexamethasone, for the treatment of relapsed or refractory MM in adults who have received one to three prior lines of therapy. Approval was based on the phase III IKEMA trial (n=302), in which the addition of isatuximab to carfilzomib/dexamethasone resulted in a 45% reduction in the risk of disease progression or death. Median PFS was not reached in the isatuximab/carfilzomib/dexamethasone arm, compared with 20.27 months in the carfilzomib/dexamethasone arm (P = 0.0032). [96] 781b155fdc


Welcome to the group! You can connect with other members, ge...
bottom of page